Pralmorelin

Product Name:Pralmorelin

Form:Acetate salt

Purity:95%

Storage:-20^oC

Cas No:158861-67-7

Molar Mass:818

Chemical Formula:C45H55N9O6

Synonyms:GHRP-2

IUPAC Name:(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide

SMILES:C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N

InChIKey:HRNLPPBUBKMZMT-RDRUQFPZSA-N

InChI:InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1

Sequence:AXAWFK

Application:Pralmorelin, also known as GH-releasing peptide-2 (GHRP-2), is a synthetic growth hormone secretagogue (GHS) that stimulates the pituitary gland to increase growth hormone (GH) secretion. It acts as a ghrelin receptor (GHS-R1a) agonist, enhancing GH release, appetite regulation, and metabolic functions. Pralmorelin is primarily used in GH deficiency diagnosis but is also being researched for muscle growth, anti-aging, and metabolic disorder treatments. Additionally, its neuroprotective and cardioprotective effects make it a promising candidate for conditions such as sarcopenia, cachexia, and neurodegenerative diseases. Ongoing studies are evaluating its therapeutic applications in endocrinology, sports medicine, and longevity research.

Current Research:Pralmorelin (GHRP-2) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue (GHS) by activating the ghrelin receptor (GHS-R1a). Unlike endogenous GH-releasing hormone (GHRH), Pralmorelin can bypass negative feedback inhibition, leading to sustained GH release. Initially developed as a diagnostic agent for GH deficiency (GHD), its applications have expanded into muscle growth, metabolic health, and neuroprotection. Growth Hormone Stimulation and Endocrine Research Pralmorelin is widely used in diagnosing GH deficiency (GHD) due to its strong ability to stimulate GH secretion. GH and IGF-1 elevation: It promotes increased circulating IGF-1 levels, which play a crucial role in muscle growth, tissue repair, and metabolic regulation. Alternative to recombinant GH therapy: Unlike direct GH injections, Pralmorelin stimulates natural GH pulsatility, reducing the risk of GH desensitization and hormonal imbalances. Potential for pediatric and adult GHD treatment: Research is assessing its long-term safety and effectiveness in managing GHD-related disorders. Muscle Growth, Sarcopenia, and Cachexia Research Due to its GH-enhancing properties, Pralmorelin is being investigated for muscle preservation and recovery. Muscle mass maintenance: Studies suggest that Pralmorelin reduces muscle atrophy in aging-related sarcopenia and chronic disease-related cachexia (e.g., cancer, chronic kidney disease). Sports medicine and recovery: Its ability to enhance GH and IGF-1 production may benefit athletes and individuals recovering from injuries. Fat metabolism and body composition: Research indicates Pralmorelin promotes lipolysis (fat breakdown), helping reduce visceral fat and improve metabolic health. Neuroprotection and Cognitive Health Pralmorelin??s role in brain function and neurodegeneration is a growing area of research. Alzheimer??s disease and cognitive decline: Studies suggest that GH secretagogues like Pralmorelin may enhance synaptic plasticity and memory retention, offering potential neuroprotective effects. Parkinson??s disease: Early research indicates that Pralmorelin may protect dopaminergic neurons, reducing oxidative stress and neuroinflammation. Cardioprotective and Metabolic Benefits Pralmorelin is being studied for its impact on cardiovascular health and metabolic disorders. Cardiac repair and heart function: Some studies indicate that Pralmorelin supports cardiac regeneration and vascular health, potentially benefiting heart failure patients. Insulin sensitivity and glucose metabolism: GH secretagogues are being explored for their effects on type 2 diabetes and metabolic syndrome, with some studies showing improvements in glucose control and insulin resistance. Emerging Research Areas Bone health and osteoporosis: Pralmorelin??s role in bone mineralization is being studied for potential applications in osteoporosis prevention. Immune function and aging: Given its influence on cell regeneration, research is evaluating Pralmorelin??s role in immune system support and longevity. Wound healing and tissue repair: Studies suggest that GH secretagogues may accelerate tissue healing, making Pralmorelin a potential candidate for surgical recovery and chronic wound management. With expanding research, Pralmorelin is emerging as a promising therapeutic agent in endocrinology, muscle regeneration, neuroprotection, and metabolic health, offering new treatment possibilities beyond GH deficiency diagnosis.

Reference:Adis Editorial. (2004). Pralmorelin: GHRP 2, GPA 748, Growth Hormone-Releasing Peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.?Drugs in R & D,?5, 236-239.